Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 0.47 |
| ▸ | PARP2 | Q9UGN5 | 8/20 | 0.47 |
| ▸ | PARP6 | Q2NL67 | 3/20 | 0.40 |
| ▸ | PARP3 | Q9Y6F1 | 3/20 | 0.40 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.40 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6114401 | 0.93 | PARP1 (0.51) | PARP1PARP2PARP6PARP3TIPARP | |
| SCHEMBL6114136 | 0.91 | PARP1 (0.52) | PARP1PARP2PARP6PARP3TNK1 | |
| SCHEMBL6114127 | 0.90 | PARP1 (0.51) | PARP1PARP2PARP6PARP3TIPARP | |
| SCHEMBL6114554 | 0.90 | PARP1 (0.49) | PARP1PARP2PARP6PARP3TIPARP | |
| SCHEMBL6114251 | 0.90 | PARP1 (0.52) | PARP1PARP2PARP6PARP3TIPARP | |
| SCHEMBL6114012 | 0.90 | PARP1 (0.48) | PARP1PARP2PARP6PARP3TIPARP | |
| SCHEMBL6114459 | 0.90 | PARP1 (0.49) | PARP1PARP2PARP6PARP3TIPARP | |
| SCHEMBL6114318 | 0.88 | PARP1 (0.47) | PARP1PARP2PARP6PARP3TIPARP | |
| SCHEMBL6114269 | 0.88 | PARP1 (0.47) | PARP1PARP2PARP6PARP3TIPARP | |
| SCHEMBL1160701 | 0.87 | PARP1 (0.55) | PARP1PARP2PARP6PARP3TNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980902-B2 | Poly (ADP-ribose) polymerase (PARP) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-17 | — | — | US | disclosed |
| US-8980902-B2 | Poly (ADP-ribose) polymerase (PARP) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-17 | — | — | US | disclosed |
| US-20140024654-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
| US-20140024654-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
| US-8541417-B2 | Poly (ADP-ribose) polymerase (PARP) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-09-24 | — | — | US | disclosed |
| US-8541417-B2 | Poly (ADP-ribose) polymerase (PARP) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-09-24 | — | — | US | disclosed |
| US-20120129868-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-24 | — | — | US | disclosed |
| US-20120129868-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129868-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885PARP2 2/4885PARP6 4/4885 |
| US-20140024654-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885PARP2 2/4885PARP6 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.